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Simulating drug binding and unbinding is a challenge, as the rugged energy landscapes that separate bound and unbound states 
require extensive sampling that consumes significant computational resources. Here, we describe the use of interactive molecular 
dynamics in virtual reality (iMD-VR) as an accurate low-cost strategy for flexible protein-ligand docking. We outline an experimental 
protocol which enables expert iMD-VR users to guide ligands into and out of the binding pockets of trypsin, neuraminidase, and HIV-
1 protease, and recreate their respective crystallographic protein-ligand binding poses within 5 – 10 minutes. Following a brief 
training phase, our studies shown that iMD-VR novices were able to generate unbinding and rebinding pathways on similar timescales 
as iMD-VR experts, with the majority able to recover binding poses within 2.15 Å RMSD of the crystallographic binding pose. These 
results indicate that iMD-VR affords sufficient control for users to carry out the detailed atomic manipulations required to dock 
flexible ligands into dynamic enzyme active sites and recover crystallographic poses, offering an interesting new approach for 
simulating drug docking and generating binding hypotheses.  
1 Introduction 
 
Computational researchers across a wide range of fields are becoming increasingly aware of their responsibility to explore 
low-cost simulation methodologies whose energy and hardware demands are environmentally sustainable. [1] Whilst the 
molecular dynamics (MD) approach to biomolecular simulation [2-5] and protein ligand-binding [6-12] has exploded in 
recent years, [13] the computational cost of MD-based approaches remains significant – a result of the fact that proteins 
are high-dimensional systems characterized by many local energy minima separated by a rugged landscape.  
 
Building on previous work constructing interactive simulation frameworks (e.g., led by Brooks [14-16], Wilson [17], Schulten 
[18, 19], and others [20-22]), we have been exploring interactive molecular dynamics in virtual reality (iMD-VR) as a low-
cost strategy for investigating biomolecular problems like protein-ligand binding. Part of the attraction of an MD-based 
approach is the fact that it can capture movement and flexibility of both the protein and the ligand. Our open-source iMD-
VR framework Narupa [23] allows users to interactively visualise and manipulate the molecular dynamics of real-time 
simulations within a virtual environment with atomic-level precision. The iMD-VR approach recognizes that the neural nets 
of the human brain, trained over several aeons, offer extremely sophisticated machinery for efficiently undertaking tasks 
linked to 3D insight, spatial navigation, and manipulation, with energy demands that are a fraction of those required by 
sophisticated hardware-accelerated machine-learning frameworks. Narupa enables humans to utilize their 3D spatial 
awareness skills, and their ability to undertake ‘on-the-fly’ reasoning, to perform sophisticated operations on complex 
three-dimensional molecular structures, giving them the ability to move molecular systems between different regions of 
configuration space. In previous work, we have demonstrated that iMD-VR has acceleration benefits for various 3D 
molecular tasks compared to two-dimensional interfaces. [23, 24] The ability to physically reach out and manipulate 
simulated systems as if they were tangible objects gives users the opportunity to explore molecular transformations, 
mechanisms, and rare events that may otherwise be inaccessible using conventional high-performance computing (HPC) 
MD simulations. While we have previously demonstrated the potential of iMD-VR to generate dynamical pathways in small 
systems, it remains to be seen whether iMD-VR is sufficiently intuitive and enables enough control for researchers to 
undertake more complex tasks. 
 
Figure 1: Interactive protein-ligand rebinding using iMD-VR. The top panel shows a schematic of Narupa, the open-source multiperson iMD-VR 
framework used to carry out the studies described herein, showing two participants using handheld wireless controllers to manipulate a real-time 
MD simulation of neuraminidase and oseltamivir. More information on the Narupa setup is available in ref 15. The bottom panel shows a three-
dimensional representation of the binding pockets of each of the three protein systems interactively undocked and redocked, each bound to a ligand. 
The trypsin graphic (A) highlights the network of hydrogen bond interactions from Asp189, Ser190, and Gly219 to benzamidine (based off PDB code 
1S0R). The neuraminidase graphic (B) highlights the hydrogen bonds between oseltamivir and both the 150-loop and a positively-charged trio of 
arginine residues of neuraminidase (based off a mutated neuraminidase structure derived from PDB code 2QWK). The HIV-1 protease graphic (C) 
highlights the hydrogen bonds between the hydroxyl group of amprenavir with both Asp25A and the protonated form of Asp25B (based off PDB code 
1HPV). For HIV-1 protease, the protein ‘flaps’ have been highlighted in purple. 
 
 
In this article, we focus on applying Narupa to unbinding and rebinding small molecules to proteins, as illustrated in Figure 
1. Applying iMD-VR to protein-ligand systems requires moving a simulation between thermodynamically and kinetically 
distinct states (i.e., bound and unbound). This requires sophisticated three-dimensional spatial reasoning: the protein 
binding pocket needs to be located, and the ligand orientated such that key contacts to specific residues are properly 
recreated. We evaluate the utility of iMD-VR to facilitate such manipulations through applications to three protein-ligand 
systems of increasing complexity, and investigate the extent to which iMD-VR  ‘experts’ and ‘novices’ were able to reversibly 
generate protein unbinding and rebinding pathways and recover crystallographic ligand poses for the systems shown in 
Figure 1. The results of the experimental protocol outlined herein show that iMD-VR users can quickly unbind and rebind 
ligands to proteins and recover experimental protein-ligand structures. For example, we show that an hour-long training 
session with an expert user enables novice iMD-VR users to recover the original binding poses for several different protein-
ligand systems. We have established that the pathways generated by iMD-VR users are reproducible, and that the binding 
poses they recover are stable when used to initiate MD simulations over longer simulation timescales.  
 
iMD-VR represents a relatively new approach to simulating drug binding,  since it involves a fully (or predominantly) flexible 
dynamic system and also does not require predefining a CV along which to carry out biased molecular dynamics simulations. 
[25] Instead, the researcher simply ‘draws’ the desired pathway by manipulating a complex system between different 
states. This approach has the potential to accelerate the exploration of pathways through high-dimensional configuration 
space. Overall, our tests show that a well-designed iMD-VR setup enables expert and novice users alike to accelerate 
complex 3D state changes of biomolecular systems. Our results suggest that iMD-VR tools are sufficiently intuitive and 
provide adequate control to enable users to recover experimentally derived bound complexes.  Moreover, the fact that the 
sampled pathways are reproducible suggests that they are not too far from the equilibrium ensemble. 
2 Methods 
2.1 System Selection 
 
The systems selected for the studies outlined herein include, at one extreme, those that have well-characterized binding 
modes, where a user with prior knowledge of the system can use iMD-VR to sample binding and unbinding pathways. At 
the other extreme, we sought to push the limits of the iMD-VR tools and examine more complex protein-ligand systems. 
The three systems we chose are shown in Figures 1 and 2 and are described below in order of increasing complexity.  
 
2.1.1 Trypsin  
 
The first protein-ligand system is the enzyme trypsin with a benzamidine ligand. Trypsin is a well-studied serine protease 
hallmarked by a catalytic triad consisting of histidine, serine and aspartic acid. As shown in Figure 1A, a secondary motif of 
the trypsin binding pocket is an additional aspartic acid residue (at position 189) that stabilises the positively charged amino 
acids, binding a peptide chain in a pose that allows for specific cleavage of the carboxyl-side chain in which these amino 
acids are present.[26] Asp189 is charged, partially-buried, and is surrounded by a water network that favours 
desolvation.[27-29]  Trypsin inhibitors can exploit this by mimicking positively-charged residues and forming an electrostatic 
contact with Asp189, an interaction further stabilized by a network of hydrogen bonds to Ser190 and Gly216 (Figure 1A).[30] 
The binding mode between trypsin and one of its inhibitors, benzamidine, has relatively fast kinetics and is therefore often 
applied as an initial use case for theoretical methods.[31-34] From an iMD-VR perspective, the trypsin-benzamidine system 
represents a binding mode where users do not need to induce significant conformational changes in the protein, and the 
ligand has only one rotatable bond. In effect, a user need only move the benzamidine out of the binding pocket before 
placing it back, making trypsin a relatively simple test case for iMD-VR.  
 
Figure 1A shows a three-dimensional binding mode of benzamidine in the secondary binding pocket of trypsin, illustrating 
how residues Asp189, Ser190, and Gly216 bind to ligands (based off PDB code 1S0R). Figure 2A shows the two-dimensional 
binding mode of two ligands, benzamidine and indole-amidine, into trypsin. Supplementary video A.1 
(https://vimeo.com/354833443) shows an example of an expert iMD-VR user unbinding and rebinding benzamidine from 
trypsin in iMD-VR.   
 
2.1.2 Neuraminidase  
 
H7N9 neuraminidase is a glycoside enzyme found on the surface of influenza virions that catalyzes the hydrolysis of sialic 
acid residues, a process integral to influenza virus mutation.[35, 36] This strain was found in the influenza virus responsible 
for the 2013 bird flu pandemic.[37] The process of influenza virus replication begins with the virus attaching itself to the 
cell via the binding of hemagglutinin (a viral cell surface protein) to sialic acid, found on the end of glycoproteins attached 
to the cell membrane. Once anchored, the virus can enter the cell and hijack its machinery in order to replicate itself. After 
new viruses have been manufactured, neuraminidase proteins cleave sialic acid groups from cellular glycoproteins, 
breaking the anchor between the virus and the host cell, freeing the new viruses to infect other cells. In recent years, there 
has been extensive research on the discovery of inhibitors that mimic sialic acid, thereby preventing the cleavage of sialic 
acid residues by neuraminidase and obstructing the release of new viruses. [38, 39] Oseltamivir (Tamiflu) is a transition 
state analogue of sialic acid and licensed therapy for influenza that binds to a triad of arginine residues in the neuraminidase 
active site (Arg118, Arg292, and Arg371) via its carboxylate group. [40] In addition to this, a crucial loop opening and closing 
mechanism, known as the 150-loop motion, is involved in the unbinding and rebinding of oseltamivir (Figure 1B). [41, 42] 
From an iMD-VR perspective, the binding of oseltamivir to neuraminidase represents a more complex task than the trypsin-
benzamidine system for two reasons: (1) Given that 150-loop movement is imperative to binding, this backbone motion 
needs to be carried out by the iMD-VR user; (2) With eight rotatable bonds, oseltamivir has considerably more 
conformational flexibility than benzamidine, making it more of a challenge to re-establish the correct bound configuration. 
Figure 1B shows a three-dimensional binding mode of oseltamivir in the active site of neuraminidase, illustrating how the 
150-loop and arginine trio binds to ligands (based off a mutated neuraminidase structure derived from PDB code 2QWK; 
details for how this was done can be found in ref [37]). Figure 2B shows the two-dimensional binding mode of two ligands, 
oseltamivir and zanamivir, into neuraminidase. Supplementary video B shows an example of an expert iMD-VR user 
unbinding and rebinding oseltamivir from neuraminidase in Narupa.   
 
2.1.3 HIV-1 protease  
 
HIV-1 protease is a viral aspartyl protease essential to the life cycle of HIV, responsible for cleaving precursor polypeptides 
into functional proteins, making it an attractive drug target for preventing HIV maturation. Structurally, HIV-1 protease is a 
homodimer that shares a single active site between two protein subunits, each of which contributes a catalytic aspartic 
acid. Mechanisms for HIV-1 protease cleavage of precursor proteins have been proposed [43]; however, it is broadly 
understood that the two aspartic acid residues each act as an acid or base respectively, activating a water molecule that 
then goes on to break peptide carbonyl bonds via nucleophilic attack. Sulfonamides are a class of drug licensed for the 
treatment of HIV that hydrogen bond to the catalytic aspartic residues and thus block protease activity [44], an example of 
which is amprenavir. Functionally, the two aspartic acids are thought to primarily exist in a monoprotonated state, 
especially when in the presence of an inhibitor [45], although it has been debated which tautomer favours amprenavir 
binding. [46-50] The HIV-1 protease active site is gated by two beta-hairpin flaps that shift through a series of different 
conformational states before ligand binding. [51] Therefore, this task requires iMD-VR users to move these flaps into an 
open position to guide amprenavir out, and then carefully place the loops back without disrupting their secondary structure. 
From an iMD-VR perspective, the motion of these flaps, combined with the higher rotational flexibility of amprenavir, makes 
this a particularly challenging binding task. Figure 1C shows a three-dimensional binding mode of amprenavir in the active 
site of HIV-1 protease, illustrating how Asp25A and Asp25B bind amprenavir (based off PDB code 1HPV). The active site 
flaps are coloured in purple. Figure 2C shows the two-dimensional binding mode of amprenavir into HIV-1 protease. 
Supplementary video C (https://vimeo.com/354834013) shows an example of an expert iMD-VR user unbinding and 
rebinding amprenavir from HIV-1 protease in Narupa.   
 
 
 
 
 
Figure 2: Summary of iMD-VR docking tasks. The ligands that were interactively unbound and rebound in a series of user tests, two for each 
of the three systems: Trypsin (A), Neuraminidase (B), and HIV-1 Protease (C). For each protein system, we devised two docking tasks, a training 
phase (where a trace representation of the ligand in the bound pose was present to guide users as shown in supplementary videos A - C), and 
a testing phase, where no trace atoms were shown. For the testing tasks, parts of the ligand which interact with key residues have been 
highlighted in lilac. For proteins A and B, where the testing task ligand differs from training, the shared scaffold between the two ligands is 
highlighted in green 
2.2 Overview of Binding and Rebinding Tasks  
 
Using these candidate protein-ligand systems, we carried out iMD-VR tests. Users were split into expert and novice cohorts. 
Expert users had extensive experience using iMD-VR to interact with molecules and had some degree of familiarity with 
the protein-ligand systems described in this paper. The experts first tested the viability of using iMD-VR to generate ligand 
unbinding and rebinding pathways. Expert iMD-VR studies were carried out to establish whether the original 
crystallographic structure could be re-established for each task. Then, a cohort of novice users were asked to carry out a 
series of unbinding and rebinding tasks, in order to control for the experts’ familiarity with iMD-VR tools and the selected 
systems. This novice users had little experience using iMD-VR but did have a scientific background in biomolecular 
simulations.  
 
2.2.1 Expert user tests  
 
Expert iMD-VR users were tasked with unbinding and rebinding three ligands from the binding pockets of three proteins: 
trypsin, neuraminidase, and HIV-1 protease, detailed in Section 2.1. Figure 1 shows a three-dimensional representation of 
each of the three experimentally derived poses that expert users were asked to recreate. In these tasks, experts were 
initially given a faint trace of the ligand atoms in the correct pose, providing a visual indication of where the ligand sits in 
the crystallographic binding pose. Experts could freely switch between interacting with either a single atom at a time or a 
group of atoms together (e.g., moving one atom of the ligand or the center of mass of the entire ligand at once). Experts 
could also add or remove positional restraints to atoms, such as when manipulating the active site flaps during the HIV-1 
protease task. Supplementary videos A-C show experts unbinding and rebinding small molecules from trypsin, 
neuraminidase and HIV-1 protease, and also show the guide trace for the position of the ligand atoms. [23] 
 
2.2.2 Novice user tests  
 
Once the iMD-VR unbinding and rebinding pathways in Narupa had been established by the expert users, novice users were 
recruited to complete unbinding and rebinding tasks with each of the three protein systems. Novice users interacted with 
each system until they felt they had correctly established a binding pose, spending approximately five minutes on each 
task. The protein-ligand systems were given in order of increasingly complexity. Figure 2 gives a summary of tasks novice 
participants were asked to complete. We recruited a total of ten novice participants in two cohorts of five (‘cohort one’ and 
‘cohort two’). Cohort one completed tasks described in 2.3.1 – 2.3.4. Cohort two completed tasks described in 2.3.1 – 2.3.4 
and 2.3.6. More detailed demographic and task information can be found in the ESI.   
 
To ensure there was a comparable level of proficiency with the Narupa iMD-VR interface prior to attempting protein-ligand 
binding, novice participants were first placed in a simulation of C60 molecules and given an opportunity to familiarize 
themselves with the controls and the interaction, as was done in previous studies. [24] Additionally, before interacting with 
each of the three protein systems described in Section 2.1, we took advantage of the multiplayer feature of Narupa: novice 
users were placed in the same iMD-VR simulation as the expert user (as shown in the Figure 1 schematic), where they could 
see a fully three-dimensional representation of the bound poses shown in Figure 1. To ensure the novices had a comparable 
level of knowledge of each system, while co-habiting the simulation space, the iMD-VR expert gave a brief background on 
the system and highlighted the interactions shown in Figure 1. 
 
Once the system had been introduced, participants were asked to complete a ‘training’ ligand unbinding-rebinding task. 
During the training phase, novices had a trace of the ligand atoms in the bound pose to help guide them. Next, participants 
were given a ‘testing’ ligand unbinding and rebinding task. A summary of the training and testing tasks for each of the three 
protein systems is shown in Figure 2. In these experiments, no trace atoms of the ligand were present, meaning that 
participants had to rely more on their chemical insight to find the correct binding pose. To control for learning effects during 
the testing phase of trypsin and neuraminidase binding, novices were asked to bind different ligands from those used during 
training. The alternative ligands were chosen on the basis of key interactions remaining between the ligand and protein in 
the training portion of the study (highlighted in lilac in Figures 2A and 2B) and sharing structural similarities (highlighted in 
green in Figures 2A and 2B). Due to a lack of availability of an appropriate alternative ligand to amprenavir, and because of 
the heightened complexity of the task owing to the number of rotatable bonds amprenavir contains, amprenavir was used 
for both the training and testing phases of the HIV-1 protease system.  Novice users also had a more limited user interface, 
where they only had the option of interacting with a single atom at a time and could not apply or remove positional 
restraints. 
 
2.3 iMD-VR simulation set up  
 
The Narupa selection utility, shown in supplementary videos A – C, allows users to select and apply visualization and 
interaction settings to a subset of atoms in a system. For all systems, the following selections were created: (a) protein 
backbone atoms, (b) key active site residues, (c) ligand atoms. Each system had some specific features, detailed below. 
Further simulation-specific details can be found in the ESI.   
 
2.3.1 Trypsin and benzamidine (expert task and novice training task) 
 
This task (Figure 2A, ‘Training’) was completed by both experts and novices. Given the relatively simple binding mode 
between benzamidine and trypsin, where the protein does not need to be manipulated by the user, the entire protein 
backbone was held in place with a positional restraint (details can be found in the ESI). To enable the user to visually identify 
the location of the active site in the protein, residues Asp189 and Ser190 were fully rendered and the backbone oxygen of 
Gly219 was shown, similar to the representation shown in Figure 1A. Additionally, supplementary video A.1 shows the 
rendering scheme used for trypsin and benzamidine. For the remaining residues, only the protein backbone was rendered. 
A trace of benzamidine in the crystallographic pose was used as a visual indication of where the ligand binds, encouraging 
the user to re-establish the original bound pose as closely as possible.   
 
2.3.2 Trypsin and indole-amidine (novice testing task) 
 
Following the training phase, novices were asked to bind indole-amidine into trypsin (Figure 2A ‘Testing’). Indole-amidine 
was selected as an alternate ligand for novices to bind as it contains the benzamidine moiety and adopts the same binding 
mode to Asp189, Ser190 and Gly219. However, unlike benzamidine, indole-amidine has a non-symmetrical extended 
scaffold that needs to be correctly orientated. This testing task used the same protein restraints and rendering scheme as 
the training task with trypsin and benzamidine (Section 2.3.1). However, no trace atoms were shown. 
 
2.3.3 Neuraminidase and oseltamivir (expert task and novice training task) 
 
This task was completed by both experts and novices. Binding oseltamivir requires a small amount of manipulation of the 
protein, as the positions of the 150-loop residues over the ligand need to be carefully maintained. However, as no significant 
shift in the tertiary structure of neuraminidase is required, all backbone atoms were held with a positional restraint (details 
can be found in the ESI). To aid in ensuring the 150-loop was correctly placed, two strategies were adopted. First, residues 
Asp151 and Arg152 of the 150-loop were fully rendered so the user could see their position. Second, a trace representation 
of the position of the 150-loop residues in the closed position was rendered so the user could see where they should be 
placed. Additionally, to show if a hydrogen bond between the carboxylic acid of oseltamivir and the arginine trio of the 
neuraminidase binding pocket had been established, Arg118, Arg292, and Arg371 were also fully rendered. For the 
remaining residues, only the backbone atoms were shown. A trace of the oseltamivir atoms in the correct position was 
used as a visual indication of where the ligand binds, ensuring that the original binding pose could be closely replicated. 
Supplementary video B shows the rendering scheme used in Narupa for neuraminidase and oseltamivir.  
 
2.3.4 Neuraminidase and zanamivir (novice testing task) 
 
Following the training phase, novice users were asked to bind zanamivir to neuraminidase. Zanamavir was selected as the 
second binding task as it is a chemical analogue to oseltamivir, sharing the same ring scaffold, carboxylic acid group, and 
hydrogen-bonding contacts to the 150-loop. However, zanamivir does exhibit some structural differences from oseltamivir; 
therefore, this task requires the user to recognize the similarity in binding modes between the two drugs. As discussed 
below, we used this particular task to examine the results obtained if we removed backbone restraints entirely. The same 
protein rendering scheme as neuraminidase and oseltamivir was used (Section 2.3.3), however, no trace atoms were 
present. 
 
2.3.5 HIV-1 protease and amprenavir (expert task) 
  
Binding small molecules to HIV-1 protease requires a significant shift in the backbone atom positions, altering the structure 
from closed to open. During the simulation, the user could toggle a positional restraint force on the active site flaps, allowing 
them to be held in place once an open or closed conformation had been established. An additional strategy to aid in the 
opening and closing of HIV-1 protease was to render trace atoms of the protein backbone in the position of the active site 
flaps in both the closed position and the open position, giving the expert user a visual indication of the range of motion the 
loop has between the two states, as well as allowing the user to closely re-establish the original closed conformation once 
amprenavir had been redocked; details on how this was done can be found in the ESI.  Aside from the active site beta-
hairpin flaps, which were manipulated by the expert user during the simulation, the protein backbone atoms were held by 
backbone restraints. Details on the positional restraints can be found in the ESI. Key contact residues Asp25A and Asp25B 
were fully rendered; the remaining amino acids only had their backbone atoms shown. A trace atom representation of 
amprenavir was used as a visual indication of where the ligand binds, ensuring the original bound conformation could be 
re-established.  
  
2.3.6 HIV-1 protease and amprenavir (novice testing and training tasks; cohort two only)  
 
Novice users from cohort two, totalling five participants, were asked to unbind and rebind amprenavir twice, once with the 
aid of trace atoms and once without. All other backbone atoms in the protein were positionally restrained. To streamline 
the task, novices were not required to open and close the HIV-1 protease flaps prior to and after binding amprenavir, 
instead starting from an HIV-1 protease conformation that had been pre-opened by an expert using iMD-VR and held with 
a positional restraint. Details of this can be found in the ESI. Both the testing and training binding tasks used the same 
rendering scheme as the expert user tests (Section 2.3.5) – the only difference between the two tasks was the presence of 
trace atoms.  
 
2.3.7 Backbone restraints  
 
During iMD-VR, users can apply force to any atom in the system – including those integral to the protein tertiary or 
quaternary structure. In order to ensure that the protein tertiary structure required for binding was not distorted, a 
positional restraint was applied to the backbone atoms in the proteins. To evaluate the impact of these restraints, we 
removed the backbone restraints for cohort two during the neuraminidase and zanamivir testing phase. A comparison of 
task completion between cohort one and cohort two for undocking and redocking zanamivir from neuraminidase can be 
found in Figure S3 of the ESI. These results, discussed in further detail in the ESI, show that careful iMD-VR users (expert 
and novice alike) were able to carry out binding and unbinding tasks without positional restraints. For analysis of iMD-VR 
trajectories, we observed that PCA carried out on iMD-VR trajectories which utilized positional restraints produced better 
results for the binding/unbinding pathways of interest, owing to diminished noise from the backbone fluctuations.  
 
2.4 Analysis of iMD-VR results  
 
For both the expert and novice interactive unbinding and rebinding tasks, trajectories of the protein-ligand system were 
recorded, taking a snapshot of the system every 0.25 ps. iMD-VR trajectories were analysed using an RMSD calculation 
protocol (described in the ESI). The RMSD was used to: (1) analyse the expert trajectories to see how the system is changed 
from a bound to unbound and back to bound state; (2) analyse novice trajectories to identify how close a user got to 
recreating the starting pose; and (3) analyse whether the recovered binding poses were stable. Specifically, we selected an 
iMD-VR frame with an RMSD close to the starting coordinates and used it to initialize a longer timescale (200 nanoseconds) 
MD trajectory. Further details can be found in the ESI.  
 
To qualitatively assess the reproducibility of the binding pathways users explored using iMD-VR, we utilized a Principal 
Component Analysis (PCA) tool called PathReducer, [52] which takes as input an xyz file containing a series of molecular 
structures (in this case, an iMD-VR-generated trajectory) and outputs the set of principal coordinates which captures the 
most structural variance in the fewest coordinates. In effect, PathReducer collapses a 3N-dimensional (where N = number 
of atoms) trajectory into a visualisable path which spans two or three dimensions. Further details of this can be found in 
the ESI.  
3.  Results and Discussion 
 
3.1 Expert unbinding and rebinding tasks 
 
3.1.1 Trypsin 
 
Figure 3A shows the RMSD of the expert user-generated trajectory of benzamidine unbinding and rebinding to trypsin, alongside the 
top two and top three PCs along the trajectory path. The RMSD plot of benzamidine shows that the original binding pose was 
recovered by the expert user, as the RMSD between the ligand at the end of the trajectory and the beginning is very low. The PCA 
results for this system showed that the direction of PC1 (the PC that captures the most structural variance along the trajectory) 
corresponds predominantly to motion of the ligand away from the protein. The value of PC1 at the end of the trajectory is very similar 
to that at the beginning, which is more evidence that this user was able to replicate the original bound pose of the drug. PC2 and PC3 
correspond to fluctuations of the backbone and side chains not in the active site of the protein, hence the trajectory not returning 
precisely to its initial value of these PCs. Supplementary animation A (https://vimeo.com/354828618) shows the trajectory generated 
by an expert user (31 picoseconds of simulation in total). Figure 4A shows the RMSD of an expert-generated rebound trypsin-
benzamidine complex over 200 nanoseconds of production MD, after solvation, minimization and equilibration as described in the 
ESI, establishing that the iMD-VR produces stable poses for this system.  
 
Expert study subjects were able to unbind benzamidine in under 5 picoseconds and obtain the rebound pose within another 5 
picoseconds (Figure 3A). Using our computing architecture, as described in the ESI, we were able to achieve MD simulation rates of 
4.45 picoseconds per minute of real time, meaning that benzamidine could be unbound and rebound on the scale of minutes. As 
such, this demonstrates the efficiency with simulations can be interactively pushed between two distinct states. Trypsin-benzamidine 
binding events have previously been observed to take nanoseconds of simulation time [32], and theoretical calculations of trypsin-
benzamidine unbinding rate constants, koff, predict millisecond dissociation times [31, 33]. To unbind or rebind benzamidine, the user 
does not need to make any major conformational changes to the binding site of trypsin, so completing this task was a matter of 
applying sufficient force to break the relatively weak electrostatic contacts between benzamidine and Asp189 and continuing to apply 
Figure 3: Recovering binding poses of three protein-ligand systems using iMD-VR. Left: Ligand RMSD of iMD-VR generated trajectories by experts 
(compared to starting coordinates): (A) trypsin and benzamidine, (B) neuraminidase and oseltamivir, and (C) HIV-1 protease and amprenavir. For 
neuraminidase, the RMSD of the 150-loop residues is shown in blue. For HIV-1 protease, the RMSD of the active site flaps backbone atoms is 
shown in blue. Right: The top two (left plots) and top three (right plots) principal components (PC1-3) for representative trajectories of the three 
protein-ligand systems. Time is represented for each trajectory by the colour of the plot, starting at purple for the beginning of the trajectory and 
yellow for the end, passing through blue and green in between. 
this force until the ligand had fully dissociated from the protein (supplementary video A.1). On rebinding, the user had to take care 
to keep the orientation of benzamidine such that the charged amidine group is pointing towards the bottom of the pocket. If the 
user attempted to bind benzamidine with the benzyl group directed towards the positively-charged Asp189 residue the ligand would 
be repelled out of the binding pocket, demonstrating the real-time responsiveness of iMD-VR to energetically unfavourable input, as 
shown in Supplementary video A.2. The video shows how, after being guided out of the binding pocket and replaced in an incorrect 
orientation, the N1 and N2 of benzamidine fail to form electrostatic contacts to Asp189, and is subsequently repelled out of the 
binding pocket, moving towards the HE1 of His57 in Trypsin, where it remains in a transiently stable pose over at least 200 ps, as 
shown in Figure S2-A1.  Supplementary video A.2 shows the expert utilizing the 3D interface of Narupa to identify those amino acids 
with which the amidine group interacts with. This alternate binding mode, in which benzamidine favours the catalytic triad and polar 
residues surrounding the binding pocket is similar to previous observations by Buch et al. [32]. Figure S2-A2 shows how it was possible 
for the expert user to apply continuous force to the benzamidine when rebinding, guiding it past the cluster of hydrophilic groups 
and into the protein core and moving it out of the protein via an alternate opening. Whilst the kinetic barriers for these pathways are 
likely to be very large; they nevertheless show the ability of iMD-VR to quickly enable exploration of new dynamical pathways. 
 
 
Figure 4: Ligand RMSD over 200 nanoseconds of molecular dynamics. Showing the RMSD of each of the three ligands (compared to the initial 
solvated, minimized and equilibrated bound coordinates) during 200 nanoseconds of molecular dynamics simulation. From top to bottom: (A) 
benzamidine (in trypsin), (B) oseltamivir (in neuraminidase), and (C) amprenavir in HIV-1 protease. 
 
3.1.2 Neuraminidase 
 
Figure 3B shows the RMSD of the expert-generated trajectory, alongside PathReducer-generated principal component plots, 
establishing that the original binding pose was recovered by the expert user. Similar to the trypsin system, PC1 is dominated by 
distances between atoms in the ligand and atoms in the protein, and so the variation along PC1 that can be seen along the trajectory 
path can be directly attributed to the removal of oseltamivir from the active site. PC2 and PC3 are again predominantly defined by 
distances between atoms in residues of the protein far from the active site, and thus fluctuations of the associated side chains lead 
to an offset in the pathway’s start and endpoints. Supplementary animation B (https://vimeo.com/354829098) shows the trajectory 
generated by an expert user (58 picoseconds of simulation time in total). Figure 4B shows the RMSD of an expert-generated rebound 
oseltamivir-neuraminidase complex over 200 nanoseconds of production MD, after solvation, minimization and equilibration as 
described in the ESI, establishing that the iMD-VR can produce stable poses for this system. 
 
Using our computing architecture, as described in the ESI, we were able to achieve MD simulation rates of 4.51 picoseconds per 
minute of simulation time, meaning that oseltamivir could be unbound and rebound on the scale of minutes of real time. Unbinding 
oseltamivir requires applying enough force to break any charged contacts or hydrogen bonds formed between the triad of positively 
charged arginine residues in the active site and the negatively charged carboxylate group of oseltamivir. Upon unbinding, the 
interactions from the amine group and carbonyl group of the drug and the two residues which comprise the 150-loop (Asp151 and 
Arg152 – see Figure 1B) were also broken, causing the loop residues to dynamically open as the drug leaves the active site  as shown 
in supplementary video B (https://vimeo.com/354833800). The backbone of the 150-loop did not dynamically open when the drug 
exited the active site as the backbone was held in place with restraints. When removing oseltamivir from the binding site, the 
molecule would occasionally flip itself over, losing the bound orientation. As such, when attempting to re-establish the correct binding 
pose, the user needed to be extremely careful to ensure that binding interactions between the drug and the 150-loop residues were 
successfully recreated, allowing the drug to flip itself back into the correct pose; if the user was too forceful, the drug would enter 
the active site in the incorrect orientation. A representation of oseltamivir ‘flipping’ as it is being removed from the neuraminidase 
binding pocket can be found in Figure S2-B1. We observed that when oseltamivir is back into the correct bound conformation, the 
two 150-loop residues will also move back into the original configuration without any input from the user, demonstrating how iMD-
VR can dynamically reform energetically-favourable contacts. 
 
3.1.3 HIV-1 Protease 
Figure 3C shows the RMSD of the expert-generated trajectory, alongside generated principal component plots, establishing that the 
original binding pose was recovered by the expert-user. The PCA results in this case are unique, as the user had to move two flaps 
capping the active site prior to removal of the bound amprenavir (discussed in more detail below, see Figure 5). Each approximately 
linear segment of the PC plots corresponds to a conformational change event: First, one flap is moved away from the active site. Then 
the second flap is moved away from the active site. Finally, the ligand is removed from the active site. This process is then reversed 
to rebind the ligand. The plots show strikingly similar pathways for unbinding and rebinding, likely as the principal coordinates are 
each capturing a significant movement of the protein backbone and thus ignoring smaller residue fluctuations; comparatively, PC2 
and PC3 in the trypsin and neuraminidase systems do not have the same starting and end points as they are ‘picking up’ protein 
fluctuations along the trajectory. Intuitively, PC1 is dominated by changes in distances corresponding to movement of the ligand out 
of the protein, PC2 corresponds predominantly to distances between the first ‘flap’ and other parts of the protein, and PC3 
corresponds predominantly to distances between the second ‘flap’ and other parts of the protein. Supplementary animation C 
(https://vimeo.com/354829412) shows the trajectory generated by an expert user (61 picoseconds simulation time in total). Figure 
4A shows the RMSD of an expert-generated rebound HIV-1 protease-amprenavir complex over 200 nanoseconds of production MD, 
after solvation, minimization and equilibration as described in the ESI. Some fluctuations to the RMSD value are observable. 
Inspection of the 200 nanosecond trajectory shows that the hydroxyl group ‘flips’ its orientation relative to the two catalytic aspartic 
acid residues, resulting in amprenavir adopting a slightly different binding pose throughout the simulation, albeit still remaining in 
the binding pocket of HIV-1 protease.  Figure 5 shows a step-by-step breakdown of the process of unbinding and rebinding amprenavir 
from HIV-1 protease, establishing that the iMD-VR can produce stable poses for this system. In the apo form, the active site flaps of 
HIV-1 protease are thought to dynamically switch between various open and closed conformations [51]. Upon binding, the once-
open flaps have a stabilizing effect by closing over the ligand. [53, 54] Experimental estimates of koff for amprenavir binding to WT 
HIV-1 protease correspond to an average binding residence time on the scale of seconds [55, 56], making it a difficult transition to 
simulate without some form of biasing. Using our computing architecture, as described in the ESI, we were able to achieve MD 
simulation rates of 4.45 picoseconds per minute of simulation time, meaning that amprenavir could be unbound and rebound – 
including opening and closing the active site flaps - on the scale of minutes of real time.  
 
 
 
 
 
 
 
 
 
 
 
Additionally, the Narupa selection language enabled the expert user to remove positional backbone restraints and move the flaps 
into an open position, before replacing the restraints and extracting amprenavir away from the binding pocket. To rebind amprenavir, 
the hydrogen bonding to Asp25A and Asp25B was reformed and, once the stable binding configuration had been found, the user 
moved the beta-hairpin flaps back into the closed conformation, again replacing the restraints. We note that we initially performed 
this task with a tautomer of HIV-1 protease where neither Asp25 residues were protonated; in this state, amprenavir seemed to 
favour a slightly different binding pose as its hydroxyl group no longer acts as a hydrogen bond acceptor. To further investigate the 
difference in binding mode between the two tautomers of HIV-1 protease, both were placed in Narupa with all positional backbone 
restraints removed. The expert user observed both binding poses without interacting with the system over 125 picoseconds of 
simulation time. In the monoprotonated HIV-1 protease system, the hydroxyl group of amprenavir rigidly points towards the 
deprotonated aspartic acid residue. Conversely, when both catalytic residues are deprotonated, the hydroxyl group frequently flips 
between pointing at either aspartic acid, causing amprenavir to ‘sag’ in the active site (see Figure S2-C1). The positively charged 
hydrogen on the protonated aspartic acid appears to have a stabilising effect on the orientation of the hydroxyl group, whereas 
removing the hydrogen causes the hydroxyl group to more easily flip as one orientation is no longer electrostatically ‘penalized’ by 
the protonated residue. Nonetheless, it is worth highlighting that Narupa enables qualitative observation of such binding dynamics 
in real time, demonstrating that iMD-VR enables both manipulation of molecular dynamics and easy comprehension of distinct 
dynamical behaviour in systems that have only small structural differences. 
 
 
Figure 5: snapshots along the interactive unbinding and rebinding of amprenavir into HIV-1 protease. The image in the upper left shows the bound “start” 
pose. (a) – (c) shown snapshots as the user unbinds amprenavir; (d) shows the unbound pose; and (e) – (g) shows snapshots as the user rebinds 
amprenavir. The corresponding RMSD time traces are shown in the middle plot, identical to that shown in Fig 3c. 
 
 
3.2 Novice unbinding and rebinding tasks 
 
Figure 6 shows the minimum achieved RMSD of each small ligand novices tried to dock in both ‘training’ and ‘testing’ phases. For 
fully flexible simulations like these, which explore a range of conformational space as a result of thermal fluctuations, there is an 
open question how to assess whether a particular simulation has successfully recovered the binding pose seen in the crystal structure. 
For example, in a recent review by Pagadala et al. [57] which evaluated several different docking software programs, they used a 
cutoff of 2 Å to determine whether or not a fully flexible docking program managed to find the ‘correct’ pose. This strategy makes 
sense for cases where the protein’s unbiased fluctuations span a range less than 2 Å.  The solid boxes in the left hand panel of Figure 
6 show the RMSD range (mean ±2s) spanned by a non-interactive Narupa simulation run for 50 picoseconds initialized in the bound 
pose at 298 K. Fig 6 shows that the ±2s range is less than 2 Å for all but the trypsin + indole-aminidine testing system. During user 
‘training’ phases, the results from Figure 6 show that all of the user generated poses are either within ±2s of the mean RMSD, or else 
have an RMSD which is within 2 Å of the crystal structure. During user ‘testing’ phases, where the binding guide was switched off and 
the ligand identity was different for trypsin and neuraminidase, the results show more scatter, exactly as we would expect. 
Nevertheless the results are encouraging. For trypsin, all of the novice-generated testing poses lie within ±2s of the mean RMSD. For 
neuraminidase and HIV-1 protease, which are considerably more complicated tasks, the results are similarly encouraging: 4/5 of the 
neuraminidase testing poses are within 2.08 Å RMSD of the crystal structure; and 3/5 of the HIV-1 protease testing poses are within 
2.15 Å RMSD of the crystal structure. Below we discuss the results for each system in further detail. 
 
3.2.1 Trypsin 
 
Directly comparing the trypsin training and testing tasks for the same participant shows that task accomplishment was better for all 
participants (ranging between 1.0Å and 1.9Å lower) during the training task. Benzamidine, used during the training task, is a small 
ligand and users had the benefit of trace atoms (Figure 6), explaining the good performance on the task. During the testing task, 
Figure 6 shows that participants were all able to recreate the amidine contact to Asp189, correctly aligning the indole-amidine 
benzamidine moiety. The variation in RMSD can be attributed to the rest of the molecule, where users had no prior guidance; 
variation in the extended scaffold between users can be seen in Figure 2A. Therefore, task accomplishment for binding indole-amidine 
into trypsin could likely be improved by providing additional feedback to indicate poses that are energetically favourable. 
 
3.2.2 Neuraminidase 
 
Figure 6 shows the minimum achieved RMSD for the neuraminidase training and testing tasks. All participants were able to recreate 
the original bound pose of oseltamivir in neuraminidase, getting within 1Å RMSD of the starting coordinates. The training results 
gave better minimum ligand RMSDs compared to the testing task, where were between 0.3Å and 3.2Å higher when the results 
between the training and testing task are compared for the same participant (Figure 6). For the testing task, four out of five 
participants were able to place zanamivir in the correct orientation, indicating that users recognized the shared scaffold between 
oseltamivir and zanamavir (highlighted in green in Figure 2B). In particular, there was very good alignment of polar moieties (e.g. the 
Figure 6: Minimum RMSD values for novice tasks. (Left) Showing the minimum achieved RMSD of each small ligand novices tried to dock, where each 
participant is assigned a unique colour. Two ligands were docked for each system, in both ‘training’ and ‘testing’ phases; each ligand is denoted in Figure 
2.  To determine the extent to which user-identified poses aligned with the native RMSD, a non-interactive Narupa simulation was run for 50 picoseconds 
in the bound pose and the average RMSD (plus or minus two standard deviations) was calculated, shown as the purple box. The whiskers at the top of 
each box span 1 Angstrom. (Right) The pose corresponding to the minimum RMSD value shown is on the left for each participant, overlaid on top of one 
another. Testing tasks for the three are shown in the top row, training tasks are shown on the bottom.  
 
carboxylate group, the ring ether) between participants (Figure 6). However, variation arose from the flexible nature of zanamivir 
(whereas oseltamivir was very consistently aligned throughout the molecule when participants completed the task with the aid of 
trace atoms). This would suggest that an interface for completing drug binding tasks using iMD-VR could benefit from being able to 
give ligand-centric feedback, indicating whether functional groups are in an optimal geometry.   
 
3.2.3 HIV-1 Protease 
 
Figure 6C shows the minimum achieved RMSD for the HIV-1 protease training and testing tasks. Likely owing to the increased size of 
amprenavir and the number of rotatable bonds it has, both the training and test tasks for HIV-1 protease had a higher degree of 
variation in minimum RMSD achieved when directly comparing results between the two tasks for the same participant. Interestingly 
however, when rebinding amprenavir a second time without trace atoms to guide them (testing task), three participants were able to 
get an RMSD close to the training task, one of which was lower by 0.08Å. This may be a result of users remembering the correct 
binding pose but it is nonetheless encouraging that iMD-VR can be used to recreate poses of larger, torsionally complex molecules 
with limited iMD-VR training. In particular, recreation of the contact between the amprenavir hydroxyl group and Asp25B was 
generally good between both tasks (Figure S4-C). For the training task, Baker-Hubbard hydrogen bond analysis [58] on the minimum 
RMSD pose confirms this all participants were able to establish this contact. In the testing task, 4/5 participants were able to orientate 
the hydroxyl group and subsequently form a hydrogen bond to the catalytic Asp25A/Asp25B catalytic residues. However, the HIV-1 
protease ‘testing’ task still had the highest variation in minimum RMSD, as some participants had a poorer performance without 
having a trace of the correct binding pose in the active site (the highest difference in RMSD between training and testing tasks was 
5.9Å). In the testing task, four participants were able to orientate the hydroxyl group and subsequently form a hydrogen bond to the 
catalytic Asp25A/Asp25B catalytic residues. However, when inspecting the two outliers, the overall scaffold of amprenavir is 
incorrectly orientated – regardless of whether the user had established the hydrogen bonding contact to Asp25A and Asp25B.      
4. Conclusions & Future Directions 
 
In this paper, we have outlined an experimental protocol for setting up an iMD-VR simulation for the purposes of 
interactively manipulating protein-ligand systems to recover experimentally derived bound poses using iMD-VR. Utilizing 
this protocol, we have carried out studies exploring iMD-VR as a strategy for interactively sampling the unbinding and 
rebinding of ligands from proteins. The iMD-VR strategy enables this process to be accelerated compared to the much 
larger timescales required in unbiased MD simulations. To the best of our knowledge, this study represents the first time 
that iMD-VR has been extended to studies of complex protein-ligand binding and unbinding dynamics. 
 
Our results show that expert iMD-VR users are able to manipulate protein-ligand systems to sample bound and unbound states. We 
also assessed the extent to which novice iMD-VR uses were able to sample binding and unbinding pathways using a training phase 
followed by a testing phase.  Overall, the training phase showed slightly better task accomplishment; however, binding was still 
generally successful for many of the users during the testing phase, with the majority of users able to get within 2.15 Å RMSD of the 
experimental crystal structure, which is a comparable level of accuracy to other fully flexible docking programs. [57] So as not to 
overwhelm participants with having to learn a new VR-rendering interface during training, we took the decision to simplify the protein 
representations as shown in Supplementary videos A – C, showing a backbone representation along with a subset of those amino 
acids which are known to have key interactions with the ligands, and which make a large contribution to the overall binding free 
energy. Encouragingly, even though only a limited set of binding interactions were shown, participants were still able to accurately 
rebind the ligands studied herein, including amprenavir, whose size and flexibility makes the binding task particularly complicated. 
This raises an interesting question: Is it the quantity of rendered interactions (i.e., showing all possible interactions) or the quality of 
rendered interactions (i.e., showing a few of the most important interactions) which enable better results to be obtained during 
interactive docking tasks? At this stage, because we have not carried out the appropriate control experiment, our results do not 
conclusively show that focusing on a few key interactions enables better results, but this is an interesting avenue of future research 
which we intend to explore in future work. Nonetheless, these results are especially encouraging given that our cohort of novice 
users had a very limited time (less than 60 minutes) to be trained in both the interface and each of the three protein-ligand 
systems. The results suggest that the iMD-VR paradigm is sufficiently intuitive and affords adequate control to enable the 
sorts of detailed manipulations required to carry out VR-enabled atomistic docking in a fully flexible MD environment. Our 
‘expert’ results show that iMD-VR users benefit from further training, given their familiarity with the interface and the 
specific protein systems.  
 
Beyond the quantitative analysis described herein, these studies also show that iMD-VR can be used to reveal interesting 
qualitative features of protein-ligand unbinding, such as benzamidine not forming electrostatic contacts to Asp189 if it is 
incorrectly orientated and subsequently being repelled out of the trypsin binding pocket (Supplementary video A.2), or 
changes in the binding of amprenavir to tautomers of HIV-1 protease. In particular, the three-dimensional interface aided 
in the identification of key interactions between the protein and the ligand, as well as allowing the user to directly observe 
dynamical behaviours in real time. 
 
Our iMD-VR framework enables users to quickly apply restraints to arbitrary subsets of atoms, which can be turned on and 
off ‘on-the-fly’. The flexible application of restraints enables the user to rapidly identify those regions where they would 
like to either explore or dampen conformational flexibility – e.g., in loop domains. As a training strategy, we have found 
that restraints enable less experienced iMD-VR users to familiarize themselves with a system without the risk of 
inadvertently damaging the tertiary structure. For expert iMD-VR users, restraints permit the sampling of sophisticated 
docking strategies that involve complex conformational changes, like that in HIV-1 protease. In future work, we intend to 
carry out more detailed studies on how to apply restraints so as to enable users to efficiently and accurately carry out 
binding tasks.  
 
We also intend to develop additional strategies to help iMD-VR users quickly formulate and test binding hypotheses. For 
example, checkpoints will enable users to return the system to previous states visited earlier in the simulation, along with 
additional audio and visual feedback to indicate to the user how structural manipulation influences the overall energy of 
the system, and allowing the user to pause the simulation and carry out energy minimizations ‘on-the-fly’. For the purposes 
of streamlining these particular studies and not overwhelming novice users, we limited the studies described herein to a 
‘backbone and key residue’ visualization scheme for the proteins. While such a representation aims to facilitate locating 
the active site and identifying key interactions, it makes it difficult to see unfavourable van der Waals interactions between 
the ligand and protein. In future work, we will examine the extent to which different rendering strategies influence task 
accomplishment. Such methods will help inform binding hypotheses in cases where the bound pose is unknown. 
 
Unbiased simulation of protein ligand-binding typically occur on timescales of milliseconds or seconds [55, 56], and is 
therefore inaccessible to even the most sophisticated simulation architectures without recourse to a biasing or acceleration 
method. There is evidence that finding minimum energy pathways in hyperdimensional systems such as these is an “NP-
hard” problem (for which no optimal method exists). [59] Having established herein that iMD-VR offers a reliable tool for 
experts and novices alike to generate accurate protein-ligand binding poses, we intend to carry out studies aimed at 
analysing the user-generated iMD-VR pathways. Specifically, we plan to analyse: (1) how closely user-generated iMD-VR 
pathways follow the system’s minimum free energy path (MFEP); and (2) methods where iMD-VR pathways may be used 
to recover free energies for association and dissociation. For example, the configurations and pathways generated from 
iMD-VR (shown in Fig 3) could serve as initial guesses for adaptive path-based free energy sampling algorithms like 
transition path sampling [60], umbrella sampling [61], path-based metadynamics [62], forward flux sampling, [63] string 
methods, [64] or boxed molecular dynamics (BXD). [65] In addition, the configurations generated during an iMD-VR run 
could be used to produce Markov state models for ligand binding systems [8], by seeding the model with initial conditions 
which are not trapped within metastable energy minima [34, 66]. Whilst there are a number of details which require further 
investigation in order to establish a reliable and integrated workflow for recovering free energies along user-generated 
iMD-VR pathways, such a framework will enable us to explore the differences in kinetics and thermodynamics between 
different ligands binding to the same protein target, or the free energy landscape of the same drug binding to different 
protein mutants, with potential applications to areas like antimicrobial resistance. More broadly, the 3D iMD-VR interface 
can be used to explore and sample cryptic binding configurations which may not be indicated in the crystal structure, 
offering exciting new opportunities for interactive drug design.    
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Supplementary Information 
 
1. Data & Video files 
The Open Science Framework (see the URL at http://doi.org/10.17605/OSF.IO/NCFQM) includes the raw simulation data utilized to 
generate all of the Figures in the main text and the SI, the associated Narupa input files, and the videos referred to within the text. 
The specific version of the Narupa software used to generate the simulations discussed in the text is available at 
https://irl.itch.io/narupaxr. The videos and animations discussed in the main text are also available on Vimeo at the following 
hyperlinks: 
Supplementary Animation A:  https://vimeo.com/354828618 
Supplementary Animation B:  https://vimeo.com/354829098 
Supplementary Animation C:  https://vimeo.com/354829412 
Supplementary Video A.1:  https://vimeo.com/354833443 
Supplementary Video A.2:  https://vimeo.com/380015176 
Supplementary Video B:  https://vimeo.com/354833800 
Supplementary Video C:  https://vimeo.com/354834013 
 
2. System parameterization 
Systems were selected where an existing crystal structure in PDB format exists. For trypsin and benzamidine, the bound complex 
coordinates were based on PDB file 1S0R. For HIV-1 protease and amprenavir, the bound complex coordinates were based on PDB 
file 1HPV. For neuraminidase and oseltamivir, the bound complex coordinates were based on the starting structures used in the 
production runs in previous work by Woods et al. (which were themselves based on PDB file 2QWK) [1]. For the user studies described 
in the main text, two additional ligand systems were identified: trypsin and indole-amidine, based on PDB file 2G5N; and 
neuraminidase and zanamivir, based on PDB file 6HCX.  
 
For performing iMD-VR runs, all proteins were parameterized with the Amber 14ffSB force field[2]. Benzamidine, indole-
amidine, zanamivir, and amprenavir were parameterized with GAFF using antechamber. If needed, hydrogens were added 
to the systems using reduce [3]. Parameters for oseltamivir were taken from Woods et al [1]. All three systems used the 
OBC2 implicit water model. All systems were energy minimized before being used as the starting coordinates for each 
bound complex. All iMD-VR simulations were run at 300K with a timestep of 0.5 fs. When interacting with atoms, we utilized 
a gaussian force, where the amount of force applied depends on the distance between the user’s controller and the atom 
they were selecting. Once users stopped interacting with a selection, the velocities of all atoms in that selection were 
reinitialized according to a Boltzmann distribution based on the temperature in order to prevent any remaining interaction 
energy in molecules propelling them past where the user intends to place them. Further details of how the velocities are 
reset can be found in ref [4]. 
 
For the expert-level tests, an 800 kJ/mol/nm2 restraint was added to all backbone atoms in both trypsin and neuraminidase; 
additionally, this restraint was applied to any Ca2+ cations embedded within both systems. An 800 kJ/mol/nm2 was applied 
to all backbone atoms in HIV-1 protease, excluding those which make up the flaps which gate the active site (defined as 
residues 49 to 55 in chain A and residues 48 to 54 in chain B). A separate force was applied to the HIV-1 flap backbone 
atoms which, unlike the other backbone restraint, the user could turn on and off during the interactive simulation. The 
software default value of 2000 kJ/mol/nm2 force constant was used for these restraints. A higher force constant is used 
compared to the backbone restraints due to their interactive nature. When a user wishes atoms to be held in place, it is 
expected that they want to be held in place firmly. All training and testing non-expert user tasks for trypsin and hiv-1 
protease had the same backbone restraints as the expert tests; these restraints were removed for the neuraminidase blind 
task for one two novice cohorts that were recruited. The other cohort used the same backbone restraints as the expert-
level test. In future work, we intend to carry out a more detailed sensitivity analysis of different restraint regimes.  
 
3. NarupaXR input files & settings  
Input files for every system discussed in this work can be downloaded from the ESI. The input files consist of a PDB structure showing 
the starting bound coordinates, an .xml file which contains the simulation information to be loaded into NarupaXR, and a .json file 
which will automatically render the molecules into the same representations used in this work. Files are compatible with NarupaXR 
version 2019.0.0; details on how to load these files into NarupaXR can be found in the version 2019.0.0 documentation.  
 
4. Equilibration protocols 
For three of the protein systems, a single frame (the minimum RMSD along the iMD-VR trajectory) was extracted from the 
simulation trajectories for production run molecular dynamics, whose results are shown in Fig 4. The extracted frame from 
trypsin had an RMSD of 0.041 for benzamidine compared to the starting coordinates. For neuraminidase the extracted 
frame had an RMSD of 0.27 for oseltamivir and 0.302 for the 150-loop compared to the starting coordinates. For HIV-1 
protease, the extracted frame had an RMSD of 0.218 for amprenavir and 1.383 for the active site flaps compared to the 
starting coordinates.   
 
Extracted frames were solvated and neutralized: 10515 water molecules and 9 Cl- ions were added to trypsin and 
benzamidine, 17956 water molecules and 1 Cl- ion were added to neuraminidase and oseltamivir, 10696 water molecules 
and 5 Cl- ions were added to HIV-1 protease and amprenavir.  All water was treated with the TIP3P water model. Forcefields 
for the protein and ligand were kept consistent between the interactive simulation and production run.  
 
The solvated frames were minimized and equilibrated using the following protocol.  Post minimization, the system was 
linearly heated over 20 ps, starting at 30K and increasing the temperature by 30K every 2 ps, until a temperature of 298K 
was reached. Next, a 10 kcal/mol/Å2 restraint was added to the protein backbone atoms and the simulation was run for 
five sets of 10ps under the NVT ensemble, reinitializing the velocities of atoms in the system before each stage. Next, any 
restraints on the protein were removed and the box volume was allowed to relax to a pressure of 1 bar by running under 
the NPT ensemble for 9 nanoseconds. Finally, the system was switched back to the NVT ensemble, before being run for a 
final nanosecond. We note that there are a number of ways which we could have chosen in order to initiate the subsequent 
200 ns MD simulations, and it is unclear a priori which choice is optimal. We chose the minimum simply because it is 
uniquely defined and unambiguous. Given that the snapshots which we extracted for production molecular dynamics were 
first solvated, minimized and then equilibrated for 10ns, the minimum RMSD structure would have been immediately 
relaxed to other nearby fluctuating structures; it is therefore unlikely that choosing the minimum as the starting point gives 
a markedly different result than choosing some other average structure nearby. 
 
The final box dimensions are as follows: For trypsin and benzamidine the dimensions were 69.109 by 66.786 by 75.289, for 
neuraminidase and oseltamivir the dimensions were 88.788 by 81.528 by 82.755, and for HIV-1 protease and amprenavir 
the final box dimensions were 68.894 by 65.427 by 78.456.  
 
5. RMSD calculation 
Narupa requires a set of atom coordinates from which to begin an iMD-VR simulation. These starting coordinates were used as the 
reference frame for the RMSD calculation. As such, the RMSD was calculated as a measure of the distance the ligand has moved 
compared to the starting frame (i.e. when it is in a bound position). To calculate the RMSD for the ligand, the protein backbone atoms 
in each step of the trajectory were aligned to those in the starting coordinates. Once the trajectory was aligned, the RMSD was taken 
for the ligand atoms compared to the starting coordinates (excluding hydrogens). However, an additional consideration is that all 
molecules tested display symmetry in some of their functional groups. Narupa allows users to quickly explore rotational orientations, 
which means that users can flip the orientation of certain rotationally invariant groups, and inadvertently introduce a degree of 
variation into RMSD calculations. Therefore, when calculating the RMSD of the ligand, symmetrical groups were identified (see figure 
S1) and the swap plugin of VMD was used to calculate a more optimal RMSD value.   
 
Additionally, to give an idea of the RMSD when docked, a ‘baseline’ RMSD was calculated by allowing each system to run for 50 ps in 
Narupa without any perturbation from the user, using a timestep of 0.5 fs and recording interval of 0.25 ps, totalling 200 RMSD data 
points. In order to gain an idea of the native behaviour of each ligand within a fully flexible protein, the backbone restraints were 
relaxed to 5 kJ/mol/nm2. In total, 60 ps of simulation time was recorded, however, the first 10 ps was discarded to give the simulation 
the opportunity to relax itself. Any ions in the system used backbone restraints of 800 kJ/mol/nm2. As with above, the RMSD was 
taken excluding the position of any hydrogens in the ligand. The RMSD value was either taken as (a) a single mean value over this 
‘reference’ trajectory or (b) a range, calculated as plus or minus two standard deviations from the mean. These values can be found 
in Table S2. A dataset containing the RMSD values for each reference trajectory of each system can be found in the supplementary 
files of the ESI.  
 
6. NarupaXR technical specifications  
Narupa consists of two components: A molecular dynamics server engine that propagates a simulation forward and 
transmits the atomistic data to a client application, which renders the simulation in VR, and provides the user interface. For 
small to moderate sized protein simulations, these two components can be run locally on the same machine. Alternatively, 
a server machine can run the simulation engine and transmit the atomistic data to other VR clients, allowing multiple people 
to interact with the same iMD-VR simulation. For the expert-level user tests, both the molecular dynamics engine and VR 
front end were run on a high-end Alienware 15 R4 gaming laptop with an Intel i7-8750H 2.20GHz CPU and a NVIDIA GeForce 
GTX 1070 graphics card. For non-expert user tests, both the molecular dynamics engine and VR front end were run on a 
high-end desktop PC with an AMD Ryzen 31200 3.10GHz CPU and a NVIDIA GeForce GTX 1060 GPU. During the novice user 
tests, an expert explained the protein system to the user in a multiplayer simulation, which required two client machines, 
with the data from the simulation engine transmitted to a computer with identical specifications over a local area network. 
 
7. Participant-generated bound poses 
Figure 6 in the main text shows an overlay of the minimum RMSD bound pose achieved by each of the five novice participants, 
showing the increased variation when participants had ghost atoms (top three images) and when they did not (bottom three images). 
Additionally, for the final 5 ps of the participant-generated trajectories in cohort 2, the distance between atoms in the ligand molecule 
with key atoms in the protein residue are shown in Figure S4. Table S1 shows the minimum RMSD of each participant for each task.  
8. Generation of HIV-1 open flap coordinates 
In order to successfully recreate the opening and closing process of HIV-1 protease, an indication of the correct open flap position 
was created by creating a ghost atom representation of the backbone atoms of open HIV-1 protease (PDB code: 1TW7) and then 
superimposing that structure over the HIV-1 protease starting coordinates. Next, an iMD-VR user took advantage of the three-
dimensional capabilities of Narupa and manually inspected the ‘hinge-point’ of the two flaps, where the positions of backbone atoms 
in the open and closed positions start to diverge. From this, a trace atom representation was created with two sets of ghost atoms, 
one for the closed and one for the open position, giving users a sense for the normal range of movement of the flaps. The areas of 
the protein backbone encapsulated by the hinge points were defined as between residues 48 and 54 on both protein chains.   
9. Docking and redocking without backbone restraints 
After establishing the usability of our framework, the experts repeated the tests with the 800 kJ/mol/nm2 backbone restraints 
removed from all simulation files. Experts were able to manipulate all three systems with minimal interference to the protein tertiary 
structure, indicating that backbone restraints can potentially be removed. However, an added benefit of using relatively high 
backbone restraints is that paths generated are more straightforward to interpret because the motion from thermal fluctuations is 
curtailed. As a result, PathReducer provides principle components which better capture the key features of user-sampled iMD-VR 
pathways (i.e. the movement of a ligand from a protein binding site rather than side chain fluctuations). For cases where loop 
displacement is important (e.g., the motion of residues in the 150-loop during the novice neuraminidase testing tasks), this can be a 
potential contributor to poor task accomplishment. For example, comparing the re-establishment of the 150-loop for the 
neuraminidase testing task where both backbone restraints are on and off, figure S5 shows that the RMSD of these key residues is 
poorer and more varied when backbone restraints are not present. Furthermore, Figure S4 shows that contact between the 
zanamavir carboxylate group and Arg371 (one of the trio of arginines which is important for binding) is consistently poor, indicating 
non-optimal placement of the ligand by participants - which is further supported by figure S3, which shows placement of the 
carboxylate group as better where backbone restraints are present. This would suggest that where placement of key residues is 
important, such as the 150-loop, backbone restraints have the benefit of restricting the degrees of freedom in a protein. For novice 
users who are unfamiliar with both iMD-VR controls and the protein system itself, a high backbone restraint gives users the ability to 
familiarize themselves with the process of undocking and redocking without fear of accidentally pushing the protein system into a 
state where binding is unfavorable.  
10. PathReducer analysis 
PathReducer takes as input an xyz file containing a series of molecular structures (in this case, an iMD-VR-generated 
trajectory) and uses principle component analysis to determine the optimal rotation and scaling of the original coordinate 
system that captures the most structural variance in the fewest coordinates. This simple rotation and scaling means that 
the resultant coordinate system is comprised of coordinates that are linear combinations of the input coordinates (or input 
‘features’). By looking at the coefficient (or ‘weight’) of each input coordinate in the new coordinate system, one can see 
the relative amount that input coordinate is contributing to the direction of the new coordinate. The projections of the 
original data onto the resultant coordinates are referred to as principal components (PCs). Plots of iMD-VR pathways in PC 
space provides an idea of the similarity of structures sampled along the pathway. These plots can also be used to understand 
the ‘route’ taken by a trajectory. Figure 3 of the main text shows the iMD-VR-generated binding and unbinding pathways 
in the space defined by their top two and top three PCs. The structures input into PathReducer were represented as squared 
interatomic distance matrices, owing to their rotational and translational invariance compared to Cartesian coordinates. 
For computational tractability, the PCA considered only those 70,000 interatomic distances that varied the most along a 
trajectory (only taking into account non-hydrogen atoms). In the plots in Figure 3 of the main text, purple corresponds to 
the beginning of the trajectory and yellow corresponds to the end, with blue and green passed through in between. Each 
scatter point is a frame from the iMD-VR trajectory, and a linear interpolation was used to connect each point. 
 
11. Demographic Information 
Novice users were recruited in two cohorts of five, totalling ten participants total. Cohort one completed the testing and training 
tasks for trypsin and neuraminidase, where all protein systems had a restraint placed on their backbone atoms. Cohort two completed 
the testing and training tasks for trypsin, neuraminidase and HIV-1 protease, however, for the neuraminidase testing task, all 
restraints were turned off.  For cohort one, of the five participants, three participants were female and one was male. One participant 
opted not to specify their gender. Four participants were between the ages of 18 and 24 and one was between the age of 25 and 34; 
one participant was an undergraduate taught student, one participant was a postgraduate taught student, and three were 
postgraduate research students. Prior experience with VR was low amongst the cohort: three participants rated themselves as having 
a little experience using VR and one participant rated themselves as somewhat experienced. One member of the cohort rated 
themselves as very experienced.  For cohort two, of the five participants, four were male and one was female; two participants were 
between the ages of 18 and 24 and three were between the ages of 25 and 34; two participants were postdoctoral researchers, two 
were postgraduate research students and one was a postgraduate taught student. Prior experience with VR was low amongst the 
cohort: two participants rated themselves as having no experience using virtual reality, two participants rated themselves as being 
slightly experienced, and one participant rated themselves as somewhat experienced. 
 
12. Additional figures and tables 
 
 
 
 
 
 
 
 
Figure S1 The symmetrical groups in each of the interactively undocked and redocked molecules. In these cases, the swap plugin of VMD 
was used so they could be treated as rotationally invariant when calculating RMSD. The atoms labelled with * are the key ligand atoms 
which participate in the distances shown in Fig S4. 
  
 
 
 
 
 
 
 
Figure S2 Snapshots of iMD-VR generated trajectories that illustrate observations by the expert level users. (A1) Shows the binding pose of 
incorrectly orientated benzamidine after being repelled from the trypsin binding pocket, in particular, how it binds to the catalytic Ser-His-
Asp triad of benzamidine (plus neighbouring Glu192) on the way out, as shown in Supplementary video A.2. (A2) shows the path trypsin 
takes when being moved by an expert iMD-VR user through the hydrophobic protein core. In this case, starting from the docked pose, the 
user was able to pull benzamidine into a binding mode where it instead sits underneath Asp189 from this pose; the user was then able to 
continue pulling benzamidine until it exited the protein through an alternative pocket. Snapshots demonstrating the motion of the ligand 
are rendered as semi-transparent purple (B1) shows oseltamivir flipping its orientation when being pulled out of the neuraminidase binding 
pocket. Snapshots demonstrating the motion of the ligand oseltamivir as rendered as transparent purple; additionally, the initial positions 
of oseltamivir and the 150-loop are rendered as semi-transparent and in the CPK colouring style. (C1) shows an alternate binding pose of 
amprenavir into a tautomer of HIV-1 protease, where neither of the catalytic aspartic acid residues are protonated, demonstrating how the 
structure of amprenavir sags when the hydroxyl group switches which aspartic acid it points towards. The starting binding pose is rendered 
as semi-transparent and purple.   
  
 
 
Figure S3 (Left) Minimum achieved RMSD for zanamivir in neuraminidase (testing task), where five participants completed the task without 
backbone restraints (cohort one) and with backbone restraints (cohort two). Each participant is assigned their own colour). (Right) Bound 
poses corresponding to minimum RMSDs shown on the left. No restraints is the top panel, restraints is the bottom panel.  
Figure S4: atom distances between key ligand atoms (labelled with * in Fig S1) and key protein residues (shown in figure 1 and 2 of the main 
text) through the final 5 ps of trajectories generated by 5 user study participants from cohort two, where each color represents the results 
generated by a different participant. The top row shows the results for training tasks, and the bottom row shows the results for testing tasks. 
The solid black line shows the system-specific average (with black dotted lines representing ±2s) for a non-interactive Narupa simulation run 
for 50 ps in the bound pose and the calculated average atom distance is shown by the blue line. For benzamidine and indole-amidine, the 
distance represents the contact between their amidine group and Asp189 of trypsin. For oseltamivir and zanamavir, the distance represents 
the contact between their carboxylic acid group and Arg371. For amprenavir, the distance represents the contact between the hydroxyl 
oxygen and the protonated catalytic residue of HIV-1 protease, Asp25B.  
 
 final 5 ps of simulation time  pose which represents the minimum RMSD achieved by each of the five participants across the six tasks described in figure 2 of 
the main text. For each task, each of the five achieved poses are overlaid on top of one another.  
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
Figure S5 shows the RMSD of the two 150-loop residues, Asp151 and Arg152, of neuraminidase for the testing task, both with and without 
backbone restraints, showing that the RMSD of the 150-loop without restraints was (a) higher and (b) exhibited a greater degree of variation 
compared to with restraints. Each participant is assigned their own color.  
 
Figure S5 Showing the atom distances for an identified key atomic contact, shown in figure 1 of the main text, through the final 5 ps of trajectories generated by 
the 5 user study participants. Additionally, for each system, the NarupaXR simulation was ran for 50 ps in the bound pose and the calculated average atom distance 
is shown by the blue line. For benzamidine and indole-amidine, the distance represents the contact between their amidine group and Asp189 of trypsin. For 
oseltamivir and zanamavir, the distance represents the contact between their carboxylic acid group and Arg371. For amprenavir, the distance represents the 
contact between the hydroxyl oxygen and the protonated catalytic residue of HIV-1 protease, Asp25B.  
 
 final 5 ps of simulation time  pose which represents the minimum RMSD achieved by each of the five participants across the six tasks described in figure 2 of 
the main text. For each task, each of the five achieved poses are overlaid on top of one another.  
 
Participant 
Ligand RMSD (Å) 
A 
training 
A 
testing 
B 
training 
B testing 
(restraints) 
B testing (no 
restraints) 
C 
training 
C 
testing 
C1 – 1 0.23 2.61 0.27 1.41 n/a n/a n/a 
C1 – 2 0.18 2.91 0.48 0.80 n/a n/a n/a 
C1 – 3 1.13 1.49 0.64 2.08 n/a n/a n/a 
C1 – 4 0.20 0.74 0.21 1.67 n/a n/a n/a 
C1 – 5 0.23 1.53 0.48 3.68 n/a n/a n/a 
C2 – 1 0.43 1.39 0.58 n/a 2.63 1.26 4.71 
C2 – 2 0.16 1.20 0.73 n/a 2.40 0.85 6.82 
C2 – 3 0.20 1.93 0.81 n/a 2.13 0.85 1.19 
C2 – 4 1.15 2.20 0.74 n/a 2.42 1.14 1.04 
C2 – 5 0.18 3.00 0.87 n/a 6.99 1.88 2.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant 
Ligand RMSD (Å) 
A 
training 
A 
testing 
B 
training 
B testing 
(restraints) 
B testing 
(no 
restraints) 
C 
training 
C 
testing 
C1 – 1 0.34 2.81 0.27 1.44 n/a n/a n/a 
C1 – 2 0.38 3.29 1.22 1.12 n/a n/a n/a 
C1 – 3 1.16 2.70 0.81 3.47 n/a n/a n/a 
C1 – 4 0.50 1.02 0.52 2.47 n/a n/a n/a 
C1 – 5 0.39 3.23 0.57 6.34 n/a n/a n/a 
C2 – 1 0.47 2.35 0.58 n/a 3.22 1.86 5.20 
C2 – 2 0.29 1.81 0.93 n/a 2.81 1.25 7.46 
C2 – 3 0.62 1.93 0.91 n/a 7.59 1.23 1.24 
C2 – 4 1.19 3.40 0.74 n/a 4.00 2.54 1.15 
C2 – 5 0.24 3.33 1.20 n/a 8.92 2.16 2.55 
Table S1 The reported minimum ligand RMSD values for each participant for each task. Protein systems are categorized by letter, where A is 
trypsin, B is neuraminidase and C is HIV-1 protease. Participants are sorted by cohort, where C1 denotes the first cohort and C2 denotes the 
second cohort. Where a participant did not complete a given task, the RMSD value is n/a.    
 
Table S2 The reported final ligand RMSD values for each participant for each task. Protein systems are categorized by letter, where A is trypsin, 
B is neuraminidase and C is HIV-1 protease. Participants are sorted by cohort, where C1 denotes the first cohort and C2 denotes the second 
cohort. Where a participant did not complete a given task, the RMSD value is n/a.    
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System Average RMSD (± 2σ) (Å) 
Benzamidine  
(A training) 
 
0.60 (± 0.30) 
Indole-Amidine 
(A testing) 
 
2.14 (± 1.23) 
Oseltamivir 
(B training) 
 
0.93 (± 0.47) 
Zanamavir 
(B testing) 
 
0.56 (± 0.31) 
Amprenavir 
(C testing and training) 
 
0.77 (± 0.40) 
Table S3 The average RMSD of each ligand used in IMD-VR docking tasks, calculated over 50 ps of simulation time. Protein systems are 
categorized by letter, where A is trypsin, B is neuraminidase and C is HIV-1 protease. Two times the standard deviation is shown in brackets. 
Each value is given to three significant figures.     
 
